Galaxy has licensed IP from Proteome Sciences for the development of a test for the diagnosis and timing of stroke onset to help inform treatment decisions.
A new study suggests binding proteins that target glucose or asparagine can be used in combination with cytolysin A-based nanopores to electrically detect the metabolites.
The mobile approach enables stroke patients to be assessed within the three-hour window for stroke treatment.
A new study has demonstrated that adding analysis of a specific type of triglyceride may improve the ability to identify individuals at risk for heart attack and stroke.
The device is an electrochemical lateral flow immunosensor test that will initially be used to detect dengue hemorrhagic fever, and later, to assess stroke severity.
A study led by Johns Hopkins describes a method for automating slow, inaccurate manual chart review when searching for signs of misdiagnosis.
The model aims to uncover stroke patients at high, medium, or low risk of cerebral amyloid angiopathy, which is linked to additional strokes or dementia.
The firm said that its wireless, non-invasive device can recognize bioimpedance asymmetry signals associated with stroke in patients with symptoms.
The levels of the metabolite could predict near- and long-term cardiovascular events or death, the research team reported.
The firm is building an antibody-based immune system-related protein biomarker test for stroke diagnosis in both community and academic hospitals.